Lehman Brothers UK Capital Funding V LP

  • ISIN: XS0301813522
  • Land: .

Nachricht vom 13.11.2017 | 18:00

Lehman Brothers UK Capital Funding V LP: Notice to Holders of Preferred Securities

DGAP-News: Lehman Brothers UK Capital Funding V LP / Key word(s): Miscellaneous

13.11.2017 / 18:00
The issuer is solely responsible for the content of this announcement.



LONDON, UNITED KINGDOM -- (Marketwired) -- 11/13/17 -- Lehman
Brothers UK Capital Funding V LP (FRANKFURT: 91SI)

TEMP:91SI

NOTICE TO THE HOLDERS OF:

USD 500,000,000 FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED
SECURITIES ('LP V ECAPS')

ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING V LP ('LP V')

ISIN: XS0301813522

LIQUIDATION OF LB GP NO.1 LTD ('the Company') AND IMPLICATIONS FOR
HOLDERS OF LP V ECAPS

THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE
REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF
APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES
RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO
BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER.

Your attention is drawn to the formal notice contained in the PDF
link below concerning the Company, LP V and the LP V ECAPS. In order
to view the formal notice, it is recommended that you copy and paste
the link into your browser.

http://www.rns-pdf.londonstockexchange.com/rns/3570W_-2017-11-13.pdf

If you have any difficulties in opening the link, please contact
Samantha Hawkins at RSM Restructuring Advisory LLP by e-mail:
Samantha.Hawkins@rsmuk.com.

Dated: 13 November 2017

This notice is given by

Bruce Alexander Mackay
RSM Restructuring Advisory LLP
as Joint Liquidator of LB GP No.1 Ltd







13.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

M1 Kliniken AG: Kursziel angehoben

Die M1 Kliniken AG hat den eingeschlagenen Wachstumskurs mit einem Umsatzanstieg von 20,3 % auch im ersten Halbjahr fortgesetzt. Analog dazu gelang es der Gesellschaft, einen überproportionalen Anstieg des EBIT um 36,5% zu erreichen und unsere Erwartungen zu übertreffen. Wir haben auf dieser Grundlage unsere Umsatz- und Ergebnisschätzungen angehoben. Bei einem Kursziel von 16,15 € ergibt sich ein hohes Kurspotenzial - damit lautet das Rating KAUFEN.

News im Fokus

ProSiebenSat.1 Media SE: Thomas Ebeling verlässt das Unternehmen Ende Februar 2018

19. November 2017, 19:10

Aktueller Webcast

ADO Properties S.A.

9M RESULTS 2017

15. November 2017

Aktuelle Research-Studie

MOLOGEN AG

Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY

20. November 2017